The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Birchbiomed’s FS2 (kynurenic acid) for the treatment…
Articles by Patricia Inácio, PhD
Pliant Therapeutics has discontinued a pivotal Phase 2b/3 clinical trial evaluating its idiopathic pulmonary fibrosis (IPF) treatment bexotegrast due…
A Phase 1 clinical trial testing Cereno Scientific’s candidate therapy for idiopathic pulmonary fibrosis (IPF) in healthy volunteers has…
Low total cholesterol levels are linked to a higher risk of death among people with idiopathic pulmonary fibrosis, a…
Brainomix, a U.K.-based software company, has joined forces with Boehringer Ingelheim, a German pharmaceutical company, to accelerate the diagnosis of pulmonary…
Acute exacerbations, or sudden bouts of symptom worsening, increase the mortality risk after lung transplantation in people with interstitial lung…
A Phase 2a trial is recruiting people with idiopathic pulmonary fibrosis (IPF) to assess the effectiveness of GRI-0621, GRI…
Bexotegrast, an oral anti-fibrotic treatment candidate from Pliant Therapeutics, is being assessed in a Phase 2b clinical trial in…
Bridge Biotherapeutics has joined the Prognostic Lung Fibrosis Consortium, known as PROLIFIC — a global nonprofit working to speed…
patientMpower and Qureight have joined forces to accelerate the discovery of new prognostic markers for interstitial lung diseases…